缩短脱敏疗程，从而开始为期两年的阿加糖酶α酶替代疗法。 - Suppr

Suppr

超能文献

Shortened desensitization leading to a 2-year enzyme replacement therapy with elosulfase alfa.

作者信息

Bekis Bozkurt Hayrunnisa, Karakurt Tuba, Cavkaytar Ozlem, Arga Mustafa

机构信息

Department of Pediatric Allergy and Immunology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.

出版信息

Ann Allergy Asthma Immunol. 2021 Aug;127(2):261-262. doi: 10.1016/j.anai.2021.04.040. Epub 2021 May 14.

DOI:10.1016/j.anai.2021.04.040

PMID:33992778

Abstract

摘要

相似文献

Shortened desensitization leading to a 2-year enzyme replacement therapy with elosulfase alfa.

Ann Allergy Asthma Immunol. 2021 Aug;127(2):261-262. doi: 10.1016/j.anai.2021.04.040. Epub 2021 May 14.

Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome.

J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1156-1157. doi: 10.1016/j.jaip.2017.02.020.

Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization.

Pediatr Allergy Immunol. 2019 Jun;30(4):491-494. doi: 10.1111/pai.13049. Epub 2019 Apr 29.

Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.

Clin Ther. 2015 May 1;37(5):1012-1021.e6. doi: 10.1016/j.clinthera.2014.11.005. Epub 2014 Dec 6.

Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).

Expert Rev Clin Pharmacol. 2016 Dec;9(12):1521-1532. doi: 10.1080/17512433.2017.1260000. Epub 2016 Nov 23.

Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.

Clin Ther. 2017 Jan;39(1):118-129.e3. doi: 10.1016/j.clinthera.2016.11.017. Epub 2016 Dec 10.

Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).

BioDrugs. 2014 Oct;28(5):465-75. doi: 10.1007/s40259-014-0108-z.

Elosulfase alfa: first global approval.

Drugs. 2014 Apr;74(6):713-8. doi: 10.1007/s40265-014-0210-z.

Is premedication a necessity before galsulfase replacement therapy?

Ann Allergy Asthma Immunol. 2016 Aug;117(2):200-2. doi: 10.1016/j.anai.2016.06.002. Epub 2016 Jun 23.

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.

J Inherit Metab Dis. 2014 Nov;37(6):979-90. doi: 10.1007/s10545-014-9715-6. Epub 2014 May 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Shortened desensitization leading to a 2-year enzyme replacement therapy with elosulfase alfa.

作者信息

Bekis Bozkurt Hayrunnisa, Karakurt Tuba, Cavkaytar Ozlem, Arga Mustafa

机构信息

Department of Pediatric Allergy and Immunology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.

出版信息

Ann Allergy Asthma Immunol. 2021 Aug;127(2):261-262. doi: 10.1016/j.anai.2021.04.040. Epub 2021 May 14.

DOI:10.1016/j.anai.2021.04.040

PMID:33992778

Abstract

摘要

相似文献

Shortened desensitization leading to a 2-year enzyme replacement therapy with elosulfase alfa.

Ann Allergy Asthma Immunol. 2021 Aug;127(2):261-262. doi: 10.1016/j.anai.2021.04.040. Epub 2021 May 14.

Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome.

J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1156-1157. doi: 10.1016/j.jaip.2017.02.020.

Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization.

Pediatr Allergy Immunol. 2019 Jun;30(4):491-494. doi: 10.1111/pai.13049. Epub 2019 Apr 29.

Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.

Clin Ther. 2015 May 1;37(5):1012-1021.e6. doi: 10.1016/j.clinthera.2014.11.005. Epub 2014 Dec 6.

Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).

Expert Rev Clin Pharmacol. 2016 Dec;9(12):1521-1532. doi: 10.1080/17512433.2017.1260000. Epub 2016 Nov 23.

Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.

Clin Ther. 2017 Jan;39(1):118-129.e3. doi: 10.1016/j.clinthera.2016.11.017. Epub 2016 Dec 10.

Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).

BioDrugs. 2014 Oct;28(5):465-75. doi: 10.1007/s40259-014-0108-z.

Elosulfase alfa: first global approval.

Drugs. 2014 Apr;74(6):713-8. doi: 10.1007/s40265-014-0210-z.

Is premedication a necessity before galsulfase replacement therapy?

Ann Allergy Asthma Immunol. 2016 Aug;117(2):200-2. doi: 10.1016/j.anai.2016.06.002. Epub 2016 Jun 23.

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.

J Inherit Metab Dis. 2014 Nov;37(6):979-90. doi: 10.1007/s10545-014-9715-6. Epub 2014 May 9.